Challenges and solutions: The present and future of cell therapies for T1D
Breakthrough T1D is funding research that supports manufactured islet cell source, survival, and protection and is also driving initiatives to…
Medical Affairs: Closing the gap between access and adoption
Breakthrough T1D's new Medical Affairs unit will address the numerous challenges contributing to the slow adoption of groundbreaking T1D therapies.
Cell therapies 101: What are stem cells and why do they matter?
Researchers are harnessing the power of stem cells to generate functional beta cells and islets, driving us closer toward type…
Cell therapy first: transplanted islets working without immunosuppressives
Today, Sana Biotechnology released significant clinical data: the first person with type 1 diabetes (T1D) who received deceased donor islets…
2024 greatest T1D hits: A glance at this year’s achievements
While we look back on 2024, we can reflect upon the incredible progress we’ve made in advancing breakthroughs toward cures…
Novel way to protect transplanted cells shows promise
A novel immune therapy called tegoprubart made by Eledon Pharmaceuticals and being tested in kidney transplant patients has the potential…
Breakthrough T1D shares the latest research at ISPAD
At the 2024 International Society for Pediatric and Adolescent Diabetes (ISPAD) Conference in Lisbon, Portugal, the world’s leading diabetes researchers,…
Breakthrough T1D and the Nobel Prizes: Connected!
It’s early October, which means the Nobel Prizes are being awarded in several categories. These prestigious awards recognize outstanding contributions…
